The strange part about a very human leukemia is that one of the smartest ways to study it may involve a tiny striped fish that looks more like a pet-store side character than a co-author on future drug research.
That is the setup in a new Leukemia paper, where researchers built a zebrafish model for KMT2A::MLLT3 leukemia, also known by its older nickname MLL-AF9 [1]. This fusion happens when pieces of two genes get stitched together after a chromosomal mix-up. In people, that mash-up can push blood-forming cells toward acute leukemia, often with a rough clinical course. In plain English: the cell’s instruction manual gets a deranged new chapter, and suddenly the blood system starts freelancing in the worst possible way.
Why this fish is not just doing aquarium cosplay
Cancer research lives and dies by models. If your model is too simple, it lies to you. If it is too expensive or too slow, it becomes the scientific version of buying a treadmill to dry laundry on.
That is why zebrafish keep showing up in blood cancer research. They are vertebrates, their blood system shares a surprising amount with ours, and they let scientists watch disease unfold in a whole living animal without waiting forever or burning through mouse-sized budgets [2,3]. For patients, that matters because better models can help researchers test ideas faster, spot weak points in a leukemia earlier, and avoid chasing treatments that only work in a lab dish having a very confident day.
What the team actually found
The researchers engineered zebrafish to express the human KMT2A::MLLT3 fusion in blood stem and progenitor cells. Over time, many of those fish developed leukemia. Not just vaguely “something is off” leukemia either. They showed enlarged blood-forming organs, disrupted tissue architecture, and abnormal blood cell populations. Some looked more myeloid, some more lymphoid, and some had weird in-between features that remind you cancer does not respect our filing cabinets [1].
Then came the part that makes model builders sit up straighter in their chairs: the leukemia was transplantable. Cells from sick fish could be transferred into other fish, where they caused leukemia again, and then again in secondary transplants [1]. That matters because transplantability is one of the best signs that a model is capturing the self-renewing, disease-propagating behavior that makes leukemia so hard to beat in real life.
The team also found that these fish leukemias carried gene-expression patterns linked to pathways like KRAS/RAF/MEK and suppression of p53-related programs, along with enrichment of known MLL target genes [1]. Translation: the fish were not just sick. They were sick in a biologically recognizable way.
Why a patient should care about a fish with bad luck
If you are a person sitting in an infusion chair, you do not need a charming sermon about zebrafish. You need to know whether this could help make treatment less brutal, more precise, or more likely to work.
That is where this gets interesting.
KMT2A-rearranged leukemias have become a major focus for targeted therapy, especially drugs that disrupt the menin-KMT2A interaction. This field moved fast enough that the FDA approved revumenib on November 15, 2024 for relapsed or refractory acute leukemia with a KMT2A translocation. That is real progress, not just conference-slide optimism in a blazer. But even with new targeted drugs, researchers still need better ways to study resistance, relapse, lineage switching, and combo treatments before those problems show up at 2 a.m. in clinic disguised as “mixed response” [4-6].
This zebrafish model could help with exactly that. Because it is a whole-animal system, scientists can ask messier, more realistic questions: Which extra mutations help the leukemia gain momentum? Which pathways make it vulnerable? Which drug combinations shut it down before it learns new tricks? Cancer cells are basically tiny anarchists with excellent adaptation skills, so having a faster way to test their escape plans is not trivial.
The bigger plot twist
There is also a conceptual win here. For years, zebrafish leukemia models have been useful, but this paper pushes the field forward by showing a stable, transplantable, genetically defined model driven by this specific fusion oncogene [1,3]. That gives researchers a better bridge between molecular theory and real-world therapeutic experiments.
Will a fish cure leukemia? No. Let us not put the zebrafish on the Nobel podium just yet. But if this model helps researchers sort promising treatments from wishful thinking faster, that could ripple outward to the people who need options now, not after another decade of elegant mouse paperwork.
And honestly, there is something oddly hopeful about that. A disease this ruthless may still give up some of its secrets to a small striped animal gliding around a tank, minding its own business, unaware it just became part of the argument against despair.
References
-
Saberi M, Delfi O, Hall CJ, Madola DWKK, Browett PJ, Kakadia PM, Bohlander SK. A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9). Leukemia. 2026. DOI: https://doi.org/10.1038/s41375-026-02953-y
-
Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021;20(8):611-628. DOI: https://doi.org/10.1038/s41573-021-00210-8
-
Varas A, Riquelme-Barros S, Valdor R, Mebus K, Zuniga-Pflucker JC, Allende ML. Zebrafish models of acute leukemias: Current models and future directions. WIREs Dev Biol. 2021;10(4):e400. DOI: https://doi.org/10.1002/wdev.400
-
Winters AC, Bernt KM. KMT2A-rearranged leukemia: the shapeshifter. Blood. 2022;140(17):1833-1835. DOI: https://doi.org/10.1182/blood.2022017645
-
Khurram MS, Abd Elmageed ZY, Kandil E, Underwood PW. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482-2495. DOI: https://doi.org/10.1038/s41375-021-01309-y
-
Issa GC, Aldoss I, DiPersio JF, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920-924. DOI: https://doi.org/10.1038/s41586-023-05812-3
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.